Tissue Repair

Tissue Repair Equity

The The Equity of Tissue Repair (TRP.AX) as of Oct 28, 2026 is 8.77 M AUD. In the previous year, The Equity was 13.91 M AUD — a change of -36.92% (lower).

Equity

8.77 MAUD

YoY

-36.92%

Last updated:

In 2026, Tissue Repair's equity was 8.77 M AUD, a -36.92% increase from the 13.91 M AUD equity in the previous year.

The Tissue Repair Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
130,000.00 AUD
Jan 1, 2020
999,904.00 AUD
Jan 1, 2021
27.07 M AUD
Jan 1, 2022
25.34 M AUD
Jan 1, 2023
21.88 M AUD
Jan 1, 2024
18.04 M AUD
Jan 1, 2025
13.91 M AUD
Jan 1, 2026
8.77 M AUD
The Tissue Repair Equity history
YEAREquityYoY
8.77 MAUD-36.92%
13.91 MAUD-22.88%
18.04 MAUD-17.56%
21.88 MAUD-13.64%
25.34 MAUD-6.41%
27.07 MAUD+2,607.56%
999,904.00AUD+669.16%
130,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tissue Repair Stock analysis

What does Tissue Repair do? Tissue Repair Ltd. develops advanced wound healing products for chronic wounds and post-cosmetic procedure care. The company is in the final stages of completing its Phase II program for TR-987, a chronic wound product, and concluded Phase IIB trials on Glucoprime, a proprietary molecule. TR Pro+ is the firm's cosmeceutical post-procedure gel product used in minimally invasive cosmetic procedures, currently focused on commercialization. The company's revenue streams include product development for TR-987, Glucoprime, and TR Pro+. Tissue Repair Ltd. targets healthcare providers and cosmetic clinics as key buyers of its products. Healthcare providers use TR-987 for chronic wound management, while cosmetic clinics utilize TR Pro+ for post-procedure care. The firm's focus on commercialization of TR Pro+ indicates a direct sales approach to these segments. The company's pipeline includes TR-987, Glucoprime, and TR Pro+ as its core products. The firm's products are developed for specific medical and cosmetic segments. TR-987 addresses chronic wound healing, a significant healthcare need, while Glucoprime is a proprietary molecule with potential for further development. TR Pro+ serves the growing cosmeceutical market for post-procedure care. The company's business model relies on advancing its pipeline through clinical trials and commercializing its products to target healthcare and cosmetic markets. Tissue Repair is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Tissue Repair's Equity

Tissue Repair's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Tissue Repair's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Tissue Repair's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Tissue Repair's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Tissue Repair’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Tissue Repair stock

The Equity of Tissue Repair is 8.77 M AUD in 2026.

The Equity of Tissue Repair changed from 13.91 M AUD to 8.77 M AUD, representing a -36.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Tissue Repair since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Tissue Repair historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tissue Repair

All Key Metrics — Tissue Repair